Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 102 publications
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 10, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Journal: Journal of the National Cancer Institute
Published: June 30, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Journal: JCO precision oncology
Published: April 03, 2025
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).
Journal: Breast (Edinburgh, Scotland)
Published: November 04, 2024
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Journal: Clinical breast cancer
Published: October 31, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Journal: JCO oncology practice
Published: July 19, 2024
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 17, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
Journal: Breast cancer research and treatment
Published: April 19, 2024
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 14, 2023
Last Updated: 09/26/2026